NYSE:MYOV - Myovant Sciences News Headlines Sign in or create an account to add this stock to your watchlist. Get Started $12.43 -0.41 (-3.19 %) (As of 05/24/2019 04:00 PM ET)Previous Close$12.43Today's Range$12.26 - $12.9852-Week Range$11.65 - $27.45Volume128,588 shsAverage Volume109,642 shsMarket Capitalization$880.21 millionP/E RatioN/ADividend YieldN/ABeta0.5 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Headlines Myovant Sciences (NYSE MYOV) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineMyovant Sciences misses by $0.04seekingalpha.com - May 24 at 5:59 PMMyovant plans to file U.S. application for relugolix in Q4seekingalpha.com - May 24 at 5:59 PMMyovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarterwww.nasdaq.com - May 24 at 5:59 PMMyovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019finance.yahoo.com - May 24 at 5:59 PMHealth Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' pleafinance.yahoo.com - May 20 at 5:07 PMMyovant Sciences Ltd.www.barrons.com - May 14 at 7:02 PMMyovant Shares Slide Despite Positive Late-Stage Data For Menstrual Bleeding Drugfinance.yahoo.com - May 14 at 7:02 PMRoivant Statement on Positive Phase 3 Results from Myovant's LIBERTY 1 Study in Uterine Fibroidsfinance.yahoo.com - May 14 at 9:52 AMMyovant's relugolix successful in late-stage uterine fibroid study; shares up 2% premarketseekingalpha.com - May 14 at 9:52 AMMyovant Sciences Announces Positive Phase 3 Results from LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroidsfinance.yahoo.com - May 14 at 9:52 AMIntroducing Myovant Sciences (NYSE:MYOV), The Stock That Dropped 23% In The Last Yearfinance.yahoo.com - May 14 at 9:52 AMMyovant Sciences' uterine fibroids combo therapy meets main goal in studyfinance.yahoo.com - May 14 at 9:52 AMMyovant stock up 1.6% after Phase 3 trial meets endpointsfinance.yahoo.com - May 14 at 9:52 AMMyovant to host conference call to discuss late-stage data on relugolixseekingalpha.com - May 13 at 6:39 PMMyovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, May 14th to Discuss Results from Phase 3 LIBERTY 1 Study Evaluating Once Daily Relugolix Combination Therapy in Women with Uterine Fibroidsfinance.yahoo.com - May 13 at 6:39 PMMyovant Sciences Ltd (MYOV) Given Consensus Rating of "Buy" by Analystswww.americanbankingnews.com - May 10 at 4:10 PMZacks: Analysts Anticipate Myovant Sciences Ltd (MYOV) to Post -$1.02 Earnings Per Sharewww.americanbankingnews.com - May 10 at 8:45 AMHere’s What Hedge Funds Think About Myovant Sciences Ltd. (MYOV)finance.yahoo.com - May 2 at 6:31 PMAduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directorswww.globenewswire.com - April 18 at 6:24 PMMyovant Sciences is Now Oversold (MYOV)www.nasdaq.com - April 17 at 5:53 PMExact Sciences appoints former Kansas governor, secretary of U.S. Dept. of Health, to its board of directorswww.bizjournals.com - March 19 at 6:24 PMExact Sciences appoints former Kansas governor, HHS secretary Sebelius to its board of directorswww.bizjournals.com - March 19 at 6:24 PMMyovant Sciences Ltdwww.bloomberg.com - March 19 at 9:53 AMMyovant Sciences Ltd. Estimate Momentumwww.nasdaq.com - March 18 at 6:30 PMMyovant- "Value Creation" in Cancer Treatmentfinance.yahoo.com - February 21 at 5:22 PMBullish Two Hundred Day Moving Average Cross - MYOVwww.nasdaq.com - February 13 at 5:36 PMMyovant Sciences up 12%seekingalpha.com - February 13 at 5:36 PMMyovant Sciences: Fiscal 3Q Earnings Snapshotfinance.yahoo.com - February 8 at 9:43 AMMyovant Provides Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2018finance.yahoo.com - February 7 at 5:32 PMAndreas Halvorsen Plunges Into Biotech Company Myovant Sciencesfinance.yahoo.com - January 11 at 5:31 PMMyovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - December 20 at 9:34 AMMYOV Makes Notable Cross Below Critical Moving Averagewww.nasdaq.com - November 9 at 4:33 PMMyovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018finance.yahoo.com - November 8 at 4:41 PMMyovant Strengthens Management Team and Adds New Directors to the Boardfinance.yahoo.com - November 7 at 9:35 AMMyovant Sciences (MYOV) Reports Complete Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancerwww.streetinsider.com - October 26 at 4:31 PMMyovant Sciences completes patient enrollment in Phase 3 HERO trial of relugolixseekingalpha.com - October 24 at 9:29 AMMyovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancerfinance.yahoo.com - October 24 at 9:29 AMMyovant's female infertility candidate MVT-602 shows encouraging action in early-stage studyseekingalpha.com - October 10 at 4:17 PMMyovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congressfinance.yahoo.com - October 10 at 4:17 PMMyovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleedingfinance.yahoo.com - October 8 at 8:56 AMDermavant Announces Changes to Leadership and Board of Directorswww.prnewswire.com - September 5 at 9:34 AMRoivant Adds Investigational Therapeutic for the Treatment of Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis to Pipelinewww.bizjournals.com - September 5 at 9:34 AMRoivant Sciences Provides Corporate Updatewww.marketwatch.com - August 28 at 9:26 AMMyovant Sciences to Participate in Two Upcoming Investor Conferencesfinance.yahoo.com - August 28 at 9:26 AMMyovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018finance.yahoo.com - August 8 at 9:37 AMForm 4 Myovant Sciences Ltd. For: Jul 23 Filed by: GUINAN MARKwww.streetinsider.com - July 25 at 9:16 AMMyovant Sciences fails to hold most of Elagolix approval-stoked gain, shares up 2%seekingalpha.com - July 24 at 4:11 PMMyovant Sciences announces pricing of common sharesseekingalpha.com - July 14 at 4:49 PMMyovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Sharesfinance.yahoo.com - July 14 at 4:49 PMMyovant Sciences Ltd. Announces $75 Million Public Offering of Common Sharesfinance.yahoo.com - July 11 at 4:25 PM This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: How is the LIBOR rate calculated? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.